However, in a sensitivity analysis of the REWIND study with dulaglutide, the relative risk reduction for a 40% or 50% decrease in eGFR was 30% and 44%, both significant, in the dulaglutide group compared to placebo, respectively.92 This lower risk of developing macroalbuminuria was also confirmed in an exploratory analysis of the ELIXA (lixisenatide) study.93 In the EXSCEL study (exenatide LAR), renal episodes were analyzed as additional microvascular episodes, and no differences were observed in the risk of episodes related to decreased eGFR, but differences were observed in the composite episode, which included decreased eGFR and macroalbuminuria, although only after adjustment94 (Table 2)
The 2026 FDA warning letter what changed On February 20, 2026, the FDA issued Strut Health a direct warning letter regarding marketing claims on its website
Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study
Inventions are ongoing to emerge in the use of VLPs for not only infectious diseases but also therapeutic applications
Growth Research Peptides Ipamorelin 10mg $125.00 Earn $6.25 back in store credit 5% back on every order over $20 Ipamorelin 10mg This item OVERVIEW Ipamorelin (10mg) is supplied by Retatrutide Peptide Australia's retatrutide-first research-peptide supplier as a high-purity lyophilised research material referenced across published growth research peptides workflows
These sources establish research context
